Research on Diagnosis, Treatment and Related Microbiota in Gastrointestinal Diseases
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Medicinal Chemistry".
Deadline for manuscript submissions: 25 November 2025 | Viewed by 197
Special Issue Editors
Interests: irritable bowel syndrome; GERD; inflammatory bowel disease
Special Issues, Collections and Topics in MDPI journals
Interests: inflammatory bowel disease; short bowel syndrome; microbiota; irritable bowel syndrome
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The human gastrointestinal (GI) tract harbors a diverse and complex microbial community that plays a crucial role in health and disease. Advances in microbiome research have deepened our understanding of how gut microbiota influences the onset, progression, and treatment response of various GI disorders. From inflammatory conditions such as inflammatory bowel disease (IBD) and eosinophilic esophagitis (EoE) to liver diseases like primary sclerosing cholangitis (PSC) and metabolic-associated steatotic liver disease (MASLD), gut dysbiosis has emerged as a key factor in pathogenesis and potential therapeutic targeting.
Short-chain fatty acids (SCFAs), gut-derived metabolites with anti-inflammatory and immune-modulating properties, illustrate the microbiota’s role in maintaining intestinal barrier function and systemic homeostasis. Their dysregulation has been implicated in conditions such as IBD, irritable bowel syndrome (IBS), and even extraintestinal diseases, including immune checkpoint inhibitor (ICI)-induced colitis—a growing concern in cancer immunotherapy. Understanding the interplay between gut microbiota, metabolic pathways, and immune responses offers promising avenues for diagnostic advancements and novel treatment strategies.
This Special Issue aims to explore the latest research on microbiota-related mechanisms, diagnostic innovations, and treatment approaches in GI diseases. We welcome original research and review articles addressing microbiota-driven biomarkers, therapeutic modulation (e.g., probiotics, prebiotics, fecal microbiota transplantation), host–microbiome interactions, and precision medicine applications in gastroenterology and hepatology.
We look forward to your valuable contributions to this Special Issue.
P.S. The Editors of this Special Issue extend their sincere gratitude to Dr. Luisa Bertin for her invaluable contributions. Her assistance in meticulous management and dedicated efforts in promoting the Special Issue have significantly enhanced its visibility and impact within the field.
Dr. Edoardo V. Savarino
Dr. Brigida Barberio
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- gut microbiota
- inflammatory bowel disease
- eosinophilic esophagitis
- primary sclerosing cholangitis
- metabolic-associated steatotic liver disease
- immune checkpoint inhibitor colitis
- dysbiosis
- prebiotics
- probiotics
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
